Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
Redeye returns following Kancera’s strategic shift to focus on cardiovascular diseases and its Q3 re...
Redeye provides a research update following the Pharmanovia’s decision to discontinue the partnershi...
ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.
Analyst Group har med Titania ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Redeye update its projections and valuation after Beyond Frames Q3 result.
Redeye briefly comments on Arise’s press release from earlier this week related to the settlement ag...
Q3 weaker, but entering Q4 with better momentum EBIT estimates cut by 3% on '25e-'26e Share is tradi...
Systemair bedöms vända tillbaka till positiv organisk tillväxt i verksamhetsårets andra kvartal.
Redeye leaves a comment following today’s announcement of a rights issue of approximately SEK36.
Solid Q3 report and unchanged outlook More sold units and more completed unsold units in Q4e Fair va...
An acquisition that opens the door for further expansion globally.
Nettoomsättningen var i linje med föregående år och är fortsatt påverkat av de längre säljcyklerna.
Redeye updates on Jumpgates following the company’s Q3 results, which was in line with our forecasts...
Redeye was negatively surprised by the lower-than-expected sales in the quarter.
